Cardiac Valve Diseases and Antiphospholipid Syndrome

Internal Medicine

Volumn 39, Issue 6, 2000, Pages 446-447

  Atsumi, Tatsuya ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

anticardiolipin antibody; lupus anticoagulant; stroke; thrombosis; vegetation

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; HUMAN; NOTE; VALVULAR HEART DISEASE;

ANTIPHOSPHOLIPID SYNDROME; HEART VALVE DISEASES; HUMANS;

EID: 0034203550     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.39.446     Document Type: Article

References (17)

1. Khamashta MA, Hughes GR. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 7: 389–394, 1995.
2. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 342: 341–344, 1993.
3. Morita H, Daido H, Suwa T, et al. Overt congestive heart failure with mitral and aortic regurgitation due to antiphospholipid syndrome in a patient with systemic lupus erythematosus. Intern Med 39: 506-511, 2000.
4. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33: 701–737, 1924.
5. D’Alton JG, Preston DN, Bormanis J, Green MS, Kraag GR: Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke 16: 512–514, 1985.
6. Khamashta MA, Cervera R, Asherson RA, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335: 1541–1544, 1990.
7. Galve E, Ordi J, Barquinero J, Evangelista A, Vilardell M, Soler-Soler J: Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 116: 293–298, 1992.
8. Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93: 1579–1587, 1996.
9. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-DelCastillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319: 817–823, 1988.
10. Del PaPa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal antibeta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40: 551-561, 1997.
11. Atsumi T, Khamashta MA, Haworth RS, et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 41: 800–807, 1998.
12. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79: 276–281, 1998.
13. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5: 196–205, 1996.
14. Pope JM, Canny CL, Bell DA: Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 90: 299–309, 1991.
15. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993–997, 1995.
16. Lockshin MD. Answers to the antiphospholipid-antibody syndrome? N Engl J Med 332: 1025–1027, 1995.
17. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27: 27–35, 1997.